US-based diaDexus has secured 510(k) clearance from US Food and Drug Administration (FDA) for its PLAC Test for lipoprotein-associated phospholipase A2 (Lp-PLA2) activity.

The new test is an enzyme assay developed for quantitative determination of Lp-PLA2 activity in human plasma and serum.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An analysis based on REGARDS showed elevated Lp-PLA2 activity levels are associated with a significant increase for risk of coronary heart disease.

REGARDS is a longitudinal trial funded by US-based National Institutes of Health (NIH) and included a group of 4,500 individuals with no prior history of cardiovascular events.

"The new test is an enzyme assay developed for the quantitative determination of Lp-PLA2 activity in human plasma and serum."

Chairman of the board at diaDexus Lori Rafield said: "The FDA’s clearance of our second test is an important step in achieving our vision of evolving from a single-product business into a multi-product company.

See Also:

"Our PLAC tests, ELISA and now Activity, are the only FDA cleared Lp-PLA2 tests to help identify the hidden risk of coronary heart disease, which includes heart attack.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This new PLAC Activity test has demonstrated robust analytical performance and can be used broadly by moderate-complexity reference labs, hospital labs, and physician office labs using a wide range of typical clinical chemistry analysers, allowing us to meaningfully expand our customer base."

The company said the first indication for the new test is for use in conjunction with clinical evaluation and patient risk assessment as an aid in predicting the risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events.

PLAC Tests are simple blood tests, which measure Lp-PLA2 levels in a patient’s blood, while the company developed and commercialised two FDA cleared PLAC Tests.